Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Limited pharmacological treatments for uterine leiomyomata (fibroids) are available. Now, two phase III trials lasting 24 weeks showed marked reduction in leiomyoma-related heavy menstrual bleeding with relugolix, a new orally active gonadotropin-releasing hormone antagonist with add-back oestrogen (to limit bone loss) and progestin (to limit endometrial changes from unopposed oestrogen).
Optoacoustic imaging enables the non-invasive and label-free imaging of the structure and function of organs, tissues and cells. This Review highlights key progress with optoacoustic imaging technology for applications in endocrinology and metabolism, with a specific focus on multispectral optoacoustic tomography and raster-scan optoacoustic mesoscopy.
Several shared mechanisms govern the development of bone and teeth. This Review summarizes these shared pathways and discusses the disorders that are related to both bone and teeth.
Obesity is linked to dysregulated cellular energetics in neoplastic and non-neoplastic cells in the tumour microenvironment. Here, Brown discusses the interdependence of metabolic pathways of oestrogen production in breast tissue and the obesity-related mechanisms that promote breast cancer growth.
More than 7,000 clinical trials are currently ongoing involving new drugs for type 2 diabetes mellitus (T2DM). This Review summarizes the novel drugs in development for T2DM that improve insulin sensitivity, stimulate insulin secretion or the incretin axis, or suppress hepatic glucose production.
